433 related articles for article (PubMed ID: 26170642)
1. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.
Jin JF; Zhu LL; Chen M; Xu HM; Wang HF; Feng XQ; Zhu XP; Zhou Q
Patient Prefer Adherence; 2015; 9():923-42. PubMed ID: 26170642
[TBL] [Abstract][Full Text] [Related]
2. Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: A primer.
Erstad BL; Barletta JF
Am J Health Syst Pharm; 2022 Jul; 79(15):1236-1244. PubMed ID: 35176754
[TBL] [Abstract][Full Text] [Related]
3. Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE.
Bell CF; Lau M; Lee M; Poulos C
Clin Rheumatol; 2021 Feb; 40(2):581-590. PubMed ID: 32623647
[TBL] [Abstract][Full Text] [Related]
4. Weight-based dosing in medication use: what should we know?
Pan SD; Zhu LL; Chen M; Xia P; Zhou Q
Patient Prefer Adherence; 2016; 10():549-60. PubMed ID: 27110105
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence.
Singham J; Greanya ED; Lau K; Erb SR; Partovi N; Yoshida EM
Ann Hepatol; 2010; 9(2):166-71. PubMed ID: 20526010
[TBL] [Abstract][Full Text] [Related]
6. Patient experience of medication administration and development of a Patient Experience and Preference Questionnaire (PEPQ) for patients with advanced or metastatic cancer.
Skalicky A; Bennett B; Raimbourg J; Lonardi S; Correll J; Lugowska I; Dixon M; Sargalo N; Martin ML
Front Pharmacol; 2024; 15():1310546. PubMed ID: 38601466
[No Abstract] [Full Text] [Related]
7. Real-world evidence and patient preference for subcutaneous
Gold R; Schmidt S; Deisenhammer F; Motte J; Richter N; Taipale K; Salmen HC; Bohland C; Schirduan K
Ther Adv Neurol Disord; 2024; 17():17562864241241382. PubMed ID: 38616781
[TBL] [Abstract][Full Text] [Related]
8. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
Van den Nest M; Glechner A; Gold M; Gartlehner G
Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
[TBL] [Abstract][Full Text] [Related]
9. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.
Desplats M; Pascart T; Jelin G; Norberciak L; Philippe P; Houvenagel E; Goeb V; Flipo RM
Clin Rheumatol; 2017 Jun; 36(6):1395-1400. PubMed ID: 28255739
[TBL] [Abstract][Full Text] [Related]
10. Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: A cross-sectional observational survey study.
Santus P; Ferrando M; Baiardini I; Radovanovic D; Fattori A; Braido F
World Allergy Organ J; 2019; 12(4):100030. PubMed ID: 31061688
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
Loo CK; Gálvez V; O'Keefe E; Mitchell PB; Hadzi-Pavlovic D; Leyden J; Harper S; Somogyi AA; Lai R; Weickert CS; Glue P
Acta Psychiatr Scand; 2016 Jul; 134(1):48-56. PubMed ID: 27028832
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
[TBL] [Abstract][Full Text] [Related]
13. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing.
Jundt JW; Browne BA; Fiocco GP; Steele AD; Mock D
J Rheumatol; 1993 Nov; 20(11):1845-9. PubMed ID: 8308768
[TBL] [Abstract][Full Text] [Related]
14. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.
McCluskie MJ; Brazolot Millan CL; Gramzinski RA; Robinson HL; Santoro JC; Fuller JT; Widera G; Haynes JR; Purcell RH; Davis HL
Mol Med; 1999 May; 5(5):287-300. PubMed ID: 10390545
[TBL] [Abstract][Full Text] [Related]
15. Glucose-lowering effect of insulin by different routes in obese and lean nonketotic diabetic patients.
Shahshahani MN; Kitabchi
J Clin Endocrinol Metab; 1978 Jul; 47(1):34-40. PubMed ID: 400713
[TBL] [Abstract][Full Text] [Related]
16. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.
Stoner KL; Harder H; Fallowfield LJ; Jenkins VA
Patient; 2014 Jul; ():. PubMed ID: 25015302
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites.
Ortega H; Yancey S; Cozens S
Clin Pharmacol Drug Dev; 2014 Jan; 3(1):57-62. PubMed ID: 27128231
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review.
Parra A; Hernández C; Prieto-Pinto L
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1017-1026. PubMed ID: 37665685
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
